Impact of locoregional treatment intensification in stampede high-risk M0 prostate cancer patients
Locoregional treatment intensification with CMT and de-intensified ADT offers significant oncologic benefits in men with SHR M0 prostate cancer, particularly in N0 patients. These findings support further investigation into combining brachytherapy and systemic therapy with de-intensified ADT in prospective trials.
Authors
- Jonathan D. Tward (ORCID: https://orcid.org/0000-0001-7765-4473)
- J S Howell
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
Publication Details
- Journal
- Brachytherapy
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.brachy.2025.09.006
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Utah
- Huntsman Cancer Institute
- Myriad Genetics
- National Institutes of Health
- National Cancer Institute